Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1986 Aug;54(2):223–233. doi: 10.1038/bjc.1986.166

In vivo characterization of a doxorubicin resistant B16 melanoma cell line.

F Formelli, C Rossi, R Supino, G Parmiani
PMCID: PMC2001516  PMID: 3741758

Abstract

A doxorubicin-resistant line of B16 melanoma (B16VDXR) was obtained in vitro by continuous exposure to increasing concentrations of doxorubicin of an in vitro line (B16V) derived from the in vivo transplanted B16 melanoma. When injected s.c. into mice, B16VDXR exhibited histological features, metastatic behaviour, doubling time and tumourigenic potential similar to those of the parental B16V line. Tumours obtained by implantation of B16VDXR, however, had longer latency and permitted a longer survival time than B16V and had, as in vitro, a higher DNA content. After i.v. inoculation, B16VDXR cells had lower lung colonizing capability compared to B16V. B16V and B16VDXR had significantly lower metastatic potential compared to the B16 melanoma from which they derived. Doxorubicin treatment significantly delayed the growth of B16 and B16V transplanted s.c. and increased the life span of animals bearing B16V. B16VDXR was resistant to doxorubicin treatment when the in vitro resistance index was greater than 100. While the doxorubicin-resistance phenotype was stable in vitro for 50 passages, in vivo the resistance phenotype was lost in 5 passages and tumours grown from s.c. inocula of mixtures of similar percentages of sensitive and resistant cells behaved as sensitive tumours. Cis-diamminedichloroplatinum (II), although marginally active in animals bearing B16V, was highly effective in B16VDXR bearing animals, suggesting a collateral cis-diamminedichloroplatinum (II) sensitivity of the B16VDXR line. After a single i.v. administration, doxorubicin reached initially, in the B16VDXR line, levels similar to those found in the B16 and B16V lines, but its release was faster from the resistant line in comparison with the sensitive ones. Doxorubicin-resistance was not overcome by more frequent treatments with doxorubicin. This doxorubicin-resistant tumour line obtained in vitro and used as a first in vivo transplant, may be a suitable metastaizing model for in vivo study of the mechanisms of resistance and of collateral sensitivity and for screening new drugs.

Full text

PDF
224

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Biedler J. L., Chang T. D., Meyers M. B., Peterson R. H., Spengler B. A. Drug resistance in Chinese hamster lung and mouse tumor cells. Cancer Treat Rep. 1983 Oct;67(10):859–867. [PubMed] [Google Scholar]
  2. Biedler J. L., Riehm H., Peterson R. H., Spengler B. A. Membrane-mediated drug resistance and phenotypic reversion to normal growth behavior of Chinese hamster cells. J Natl Cancer Inst. 1975 Sep;55(3):671–680. doi: 10.1093/jnci/55.3.671. [DOI] [PubMed] [Google Scholar]
  3. D'Incalci M., Torti L., Damia G., Erba E., Morasca L., Garattini S. Ovarian reticular cell sarcoma of the mouse (M5076) made resistant to cyclophosphamide. Cancer Res. 1983 Dec;43(12 Pt 1):5674–5680. [PubMed] [Google Scholar]
  4. Elbe B., Nowak C., Arnold W., Bender E. Untersuchungen über den Einflubb einer Vorbehandlung mit Cyclophosphamid, Ribo-Azauracil und Mercaleukin auf die experimentelle Metastasierung im syngenen Tumor-Wirt-System: II. Auf chemisch induzierte Sarkome von Maus und Ratte. Arch Geschwulstforsch. 1973;41(2):137–145. [PubMed] [Google Scholar]
  5. Formelli F., Carsana R., Pollini C. Comparative pharmacokinetics and metabolism of doxorubicin and 4-demethoxy-4'-O-methyldoxorubicin in tumor-bearing mice. Cancer Chemother Pharmacol. 1986;16(1):15–21. doi: 10.1007/BF00255280. [DOI] [PubMed] [Google Scholar]
  6. Giavazzi R., Scholar E., Hart I. R. Isolation and preliminary characterization of an Adriamycin-resistant murine fibrosarcoma cell line. Cancer Res. 1983 May;43(5):2216–2222. [PubMed] [Google Scholar]
  7. Hart I. R., Talmadge J. E., Fidler I. J. Comparative studies on the quantitative analysis of experimental metastatic capacity. Cancer Res. 1983 Jan;43(1):400–402. [PubMed] [Google Scholar]
  8. Howell N., Belli T. A., Zaczkiewicz L. T., Belli J. A. High-level, unstable adriamycin resistance in a Chinese hamster mutant cell line with double minute chromosomes. Cancer Res. 1984 Sep;44(9):4023–4029. [PubMed] [Google Scholar]
  9. Inaba M., Kobayashi H., Sakurai Y., Johnson R. K. Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia. Cancer Res. 1979 Jun;39(6 Pt 1):2200–2203. [PubMed] [Google Scholar]
  10. Kreider J. W., Schmoyer M. E. Spontaneous maturation and differentiation of B16 melanoma cells in culture. J Natl Cancer Inst. 1975 Sep;55(3):641–647. doi: 10.1093/jnci/55.3.641. [DOI] [PubMed] [Google Scholar]
  11. Mattern J., Wayss K., Volm M. Effect of five antineoplastic agents on tumor xenografts with different growth rates. J Natl Cancer Inst. 1984 Jun;72(6):1335–1339. [PubMed] [Google Scholar]
  12. McMillan T. J., Stephens T. C., Steel G. G. Development of drug resistance in a murine mammary tumour. Br J Cancer. 1985 Dec;52(6):823–832. doi: 10.1038/bjc.1985.265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Nicolin A., Vadlamudi S., Goldin A. Antigenicity of L1210 leukemic sublines induced by drugs. Cancer Res. 1972 Apr;32(4):653–657. [PubMed] [Google Scholar]
  14. Nowak C., Elbe B., Arnold W., Bender E. Untersuchungen über den Einfluss einer Vorbehandlung mit Cyclophosphamid, Ribo-Azauracil und Mercaleukin auf die experimentelle Metastasierung im syngenen Tumor-Wirt-System. I. Auf ein spontanes Mammakarzinom der Maus. Arch Geschwulstforsch. 1973;41(1):1–11. [PubMed] [Google Scholar]
  15. Parsons P. G., Morrison L. Melphalan-induced chromosome damage in sensitive and resistant human melanoma cell lines. Int J Cancer. 1978 Apr 15;21(4):438–443. doi: 10.1002/ijc.2910210407. [DOI] [PubMed] [Google Scholar]
  16. Price J. E., Carr D., Tarin D. Spontaneous and induced metastasis of naturally occurring tumors in mice: analysis of cell shedding into the blood. J Natl Cancer Inst. 1984 Dec;73(6):1319–1326. [PubMed] [Google Scholar]
  17. Riordan J. R., Ling V. Genetic and biochemical characterization of multidrug resistance. Pharmacol Ther. 1985;28(1):51–75. doi: 10.1016/0163-7258(85)90082-8. [DOI] [PubMed] [Google Scholar]
  18. Rogan A. M., Hamilton T. C., Young R. C., Klecker R. W., Jr, Ozols R. F. Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science. 1984 Jun 1;224(4652):994–996. doi: 10.1126/science.6372095. [DOI] [PubMed] [Google Scholar]
  19. Schabel F. M., Jr, Skipper H. E., Trader M. W., Laster W. R., Jr, Griswold D. P., Jr, Corbett T. H. Establishment of cross-resistance profiles for new agents. Cancer Treat Rep. 1983 Oct;67(10):905–922. [PubMed] [Google Scholar]
  20. Seeber S., Osieka R., Schmidt C. G., Achterrath W., Crooke S. T. In vivo resistance towards anthracyclines, etoposide, and cis-diamminedichloroplatinum(II). Cancer Res. 1982 Nov;42(11):4719–4725. [PubMed] [Google Scholar]
  21. Stackpole C. W., Alterman A. L., Fornabaio D. M. Growth characteristics of clonal cell populations constituting a B16 melanoma metastasis model system. Invasion Metastasis. 1985;5(3):125–143. [PubMed] [Google Scholar]
  22. Stackpole C. W. Distinct lung-colonizing and lung-metastasizing cell populations in B16 mouse melanoma. Nature. 1981 Feb 26;289(5800):798–800. doi: 10.1038/289798a0. [DOI] [PubMed] [Google Scholar]
  23. Stackpole C. W., Fornabaio D. M., Alterman A. L. Phenotypic interconversion of B16 melanoma clonal cell populations: relationship between metastasis and tumor growth rate. Int J Cancer. 1985 May 15;35(5):667–674. doi: 10.1002/ijc.2910350516. [DOI] [PubMed] [Google Scholar]
  24. Supino R., Prosperi E., Formelli F., Mariani M., Parmiani G. Characterization of a doxorubicin-resistant murine melanoma line: studies on cross-resistance and its circumvention. Br J Cancer. 1986 Jul;54(1):33–42. doi: 10.1038/bjc.1986.149. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES